Century Therapeutics, Inc. (IPSC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Century Therapeutics: A Biotech With Interesting Optionality Opportunities
Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return potential for risk-tolerant investors. IPSC pivoted from oncology to autoimmune CAR cells and CNTY-813 for Type 1 diabetes, now the pipeline's main value driver. Recent management actions reduced quarterly cash burn from $35M to $20M, extending runway to Q1 2028 after a 134% dilutive PIPE.
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and humoral immunity, potentially offering superior long-term engraftment and immune escape versus competitors like SANA, VRTX, and CRSP. With cash runway to Q1 2029 and a recent $135M PIPE from major biotech funds, IPSC is well-capitalized to advance its T1DM program toward IND submission in 2026 and initial clinical data in 2027.
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Century Therapeutics (IPSC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago.
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
